Halozyme Therapeutics (HALO) Return on Sales (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Return on Sales data on file, last reported at 0.0% in Q1 2026.

• Return on Sales for Q1 2026 came in at 0.0%, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.0% (changed 0.0% YoY), and the FY2025 annual result was 0.0%, changed 0.0% from the prior year.
• Return on Sales advanced to 0.0% in Q1 2026 per HALO's latest filing, from 0.0% in the prior quarter.
• Over five years, Return on Sales peaked at 0.01% in Q1 2022 and troughed at 0.0% in Q4 2025.
• A 5-year average of 0.0% and a median of 0.0% in 2024 frame the typical range for Return on Sales.
• On a YoY basis, Return on Sales climbed as much as 0 bps in 2022 and fell as far as 2 bps in 2022.
• A 5-year view of Return on Sales shows it stood at 0.0% in 2022, then rose by 17 bps to 0.0% in 2023, then climbed by 24 bps to 0.0% in 2024, then sank by 168 bps to 0.0% in 2025, then surged by 227 bps to 0.0% in 2026.
• Business Quant data shows HALO's Return on Sales at 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.